Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
Travere Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Travere Therapeutics, Inc. (TVTX)
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
Levi & Korsinsky Announces an Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
Travere Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - TVTX
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
Investors Who Lost Money on Travere Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - TVTX
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
ATTENTION Travere Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
